309 related articles for article (PubMed ID: 30614773)
1. Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi.
Khan S; Parrillo M; Gutierrez AH; Terry FE; Moise L; Martin WD; De Groot AS
Hum Vaccin Immunother; 2020; 16(2):214-227. PubMed ID: 30614773
[TBL] [Abstract][Full Text] [Related]
2. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
[TBL] [Abstract][Full Text] [Related]
3. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).
Sedegah M; Kim Y; Ganeshan H; Huang J; Belmonte M; Abot E; Banania JG; Farooq F; McGrath S; Peters B; Sette A; Soisson L; Diggs C; Doolan DL; Tamminga C; Villasante E; Hollingdale MR; Richie TL
Malar J; 2013 Jun; 12():185. PubMed ID: 23738590
[TBL] [Abstract][Full Text] [Related]
4. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
Waitumbi JN; Anyona SB; Hunja CW; Kifude CM; Polhemus ME; Walsh DS; Ockenhouse CF; Heppner DG; Leach A; Lievens M; Ballou WR; Cohen JD; Sutherland CJ
PLoS One; 2009 Nov; 4(11):e7849. PubMed ID: 19924281
[TBL] [Abstract][Full Text] [Related]
5. Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse
Noe AR; Terry FE; Schanen BC; Sassano E; Hindocha P; Phares TW; Moise L; Christen JM; Tucker KD; Kotraiah V; Drake DR; Martin WD; De Groot AS; Gutierrez GM
Front Immunol; 2021; 12():689920. PubMed ID: 34168657
[TBL] [Abstract][Full Text] [Related]
6. RTS,S/AS01
Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.
Zeeshan M; Alam MT; Vinayak S; Bora H; Tyagi RK; Alam MS; Choudhary V; Mittra P; Lumb V; Bharti PK; Udhayakumar V; Singh N; Jain V; Singh PP; Sharma YD
PLoS One; 2012; 7(8):e43430. PubMed ID: 22912873
[TBL] [Abstract][Full Text] [Related]
8. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
Chaudhury S; MacGill RS; Early AM; Bolton JS; King CR; Locke E; Pierson T; Wirth DF; Neafsey DE; Bergmann-Leitner ES
Vaccine; 2021 Feb; 39(6):968-975. PubMed ID: 33431225
[TBL] [Abstract][Full Text] [Related]
9. Identification of Plasmodium falciparum circumsporozoite protein-specific CD8+ T cell epitopes in a malaria exposed population.
Kusi KA; Aggor FE; Amoah LE; Anum D; Nartey Y; Amoako-Sakyi D; Obiri-Yeboah D; Hollingdale M; Ganeshan H; Belmonte M; Peters B; Kim Y; Tetteh J; Kyei-Baafour E; Dodoo D; Villasante E; Sedegah M
PLoS One; 2020; 15(2):e0228177. PubMed ID: 32040522
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
Alloueche A; Milligan P; Conway DJ; Pinder M; Bojang K; Doherty T; Tornieporth N; Cohen J; Greenwood BM
Am J Trop Med Hyg; 2003 Jan; 68(1):97-101. PubMed ID: 12556156
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
Agnandji ST; Fernandes JF; Bache EB; Ramharter M
Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
RTS,S Clinical Trials Partnership
PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
[TBL] [Abstract][Full Text] [Related]
14. Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.
Gandhi K; Thera MA; Coulibaly D; Traoré K; Guindo AB; Ouattara A; Takala-Harrison S; Berry AA; Doumbo OK; Plowe CV
PLoS One; 2014; 9(7):e101783. PubMed ID: 24992338
[TBL] [Abstract][Full Text] [Related]
15. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
18. Identification and Immune Assessment of T Cell Epitopes in Five
Kotraiah V; Phares TW; Terry FE; Hindocha P; Silk SE; Nielsen CM; Moise L; Tucker KD; Ashfield R; Martin WD; De Groot AS; Draper SJ; Gutierrez GM; Noe AR
Front Immunol; 2021; 12():690348. PubMed ID: 34305923
[TBL] [Abstract][Full Text] [Related]
19. RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally.
Pringle JC; Carpi G; Almagro-Garcia J; Zhu SJ; Kobayashi T; Mulenga M; Bobanga T; Chaponda M; Moss WJ; Norris DE
Sci Rep; 2018 Apr; 8(1):6622. PubMed ID: 29700348
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
Elife; 2022 Jan; 11():. PubMed ID: 35060479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
